140 related articles for article (PubMed ID: 7518471)
1. Generation and characterization of a mouse/human chimeric antibody directed against extracellular matrix protein tenascin.
He X; Archer GE; Wikstrand CJ; Morrison SL; Zalutsky MR; Bigner DD; Batra SK
J Neuroimmunol; 1994 Jul; 52(2):127-37. PubMed ID: 7518471
[TBL] [Abstract][Full Text] [Related]
2. Mouse/human chimeric Me1-14 antibody: genomic cloning of the variable region genes, linkage to human constant region genes, expression, and characterization.
Batra SK; Niswonger ML; Wikstrand CJ; Pegram CN; Zalutsky MR; Morrison SL; Bigner DD
Hybridoma; 1994 Apr; 13(2):87-97. PubMed ID: 8050781
[TBL] [Abstract][Full Text] [Related]
3. Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent.
Reist CJ; Bigner DD; Zalutsky MR
Clin Cancer Res; 1998 Oct; 4(10):2495-502. PubMed ID: 9796983
[TBL] [Abstract][Full Text] [Related]
4. Chimeric anti-tenascin antibody 81C6: increased tumor localization compared with its murine parent.
Zalutsky MR; Archer GE; Garg PK; Batra SK; Bigner DD
Nucl Med Biol; 1996 May; 23(4):449-58. PubMed ID: 8832699
[TBL] [Abstract][Full Text] [Related]
5. Improved therapeutic efficacy of a monoclonal antibody radioiodinated using N-succinimidyl-3-(tri-n-butylstannyl)benzoate.
Schuster JM; Garg PK; Bigner DD; Zalutsky MR
Cancer Res; 1991 Aug; 51(16):4164-9. PubMed ID: 1714341
[TBL] [Abstract][Full Text] [Related]
6. Treatment of intracranial human glioma xenografts with 131I-labeled anti-tenascin monoclonal antibody 81C6.
Lee Y; Bullard DE; Humphrey PA; Colapinto EV; Friedman HS; Zalutsky MR; Coleman RE; Bigner DD
Cancer Res; 1988 May; 48(10):2904-10. PubMed ID: 2452014
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic efficacy of antiglioma mesenchymal extracellular matrix 131I-radiolabeled murine monoclonal antibody in a human glioma xenograft model.
Lee YS; Bullard DE; Zalutsky MR; Coleman RE; Wikstrand CJ; Friedman HS; Colapinto EV; Bigner DD
Cancer Res; 1988 Feb; 48(3):559-66. PubMed ID: 2446747
[TBL] [Abstract][Full Text] [Related]
8. Distribution and dosimetry of I-123-labeled monoclonal antibody 81C6 in patients with anaplastic glioma.
Schold SC; Zalutsky MR; Coleman RE; Glantz MJ; Friedman AH; Jaszczak RJ; Bigner SH; Bigner DD
Invest Radiol; 1993 Jun; 28(6):488-96. PubMed ID: 7686539
[TBL] [Abstract][Full Text] [Related]
9. Preparation and characterization of anti-tenascin monoclonal antibody-streptavidin conjugates for pretargeting applications.
Foulon CF; Bigner DD; Zalutsky MR
Bioconjug Chem; 1999; 10(5):867-76. PubMed ID: 10502355
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies.
Zalutsky MR; Moseley RP; Coakham HB; Coleman RE; Bigner DD
Cancer Res; 1989 May; 49(10):2807-13. PubMed ID: 2469537
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibody localization in subcutaneous and intracranial human glioma xenografts: paired-label and imaging analysis.
Bourdon MA; Coleman RE; Blasberg RG; Groothuis DR; Bigner DD
Anticancer Res; 1984; 4(3):133-40. PubMed ID: 6465851
[TBL] [Abstract][Full Text] [Related]
12. Construction and expression of two mouse-human chimeric antibodies with high specificity and affinity for carcinoembryonic antigen.
Arakawa F; Haruno M; Kuroki M; Kanda H; Watanabe T; Misumi Y; Matsuoka Y
Hybridoma; 1993 Aug; 12(4):365-79. PubMed ID: 8244416
[TBL] [Abstract][Full Text] [Related]
13. Enhanced tumor localization and in vivo stability of a monoclonal antibody radioiodinated using N-succinimidyl 3-(tri-n-butylstannyl)benzoate.
Zalutsky MR; Noska MA; Colapinto EV; Garg PK; Bigner DD
Cancer Res; 1989 Oct; 49(20):5543-9. PubMed ID: 2477144
[TBL] [Abstract][Full Text] [Related]
14. Cloning and high level expression of a chimeric antibody with specificity for human carcinoembryonic antigen.
Beidler CB; Ludwig JR; Cardenas J; Phelps J; Papworth CG; Melcher E; Sierzega M; Myers LJ; Unger BW; Fisher M
J Immunol; 1988 Dec; 141(11):4053-60. PubMed ID: 3141512
[TBL] [Abstract][Full Text] [Related]
15. Chimeric anti-ganglioside GM2 antibody with antitumor activity.
Nakamura K; Koike M; Shitara K; Kuwana Y; Kiuragi K; Igarashi S; Hasegawa M; Hanai N
Cancer Res; 1994 Mar; 54(6):1511-6. PubMed ID: 8137257
[TBL] [Abstract][Full Text] [Related]
16. Comparative localization of glioma-reactive monoclonal antibodies in vivo in an athymic mouse human glioma xenograft model.
Wikstrand CJ; McLendon RE; Carrel S; Kemshead JT; Mach JP; Coakham HB; de Tribolet N; Bullard DE; Zalutsky MR; Bigner DD
J Neuroimmunol; 1987 May; 15(1):37-56. PubMed ID: 3571486
[TBL] [Abstract][Full Text] [Related]
17. Generation and characterization of a recombinant/chimeric B72.3 (human gamma 1).
Hutzell P; Kashmiri S; Colcher D; Primus FJ; Hand PH; Roselli M; Finch M; Yarranton G; Bodmer M; Whittle N
Cancer Res; 1991 Jan; 51(1):181-9. PubMed ID: 1988082
[TBL] [Abstract][Full Text] [Related]
18. The localisation of radiolabelled murine monoclonal antibody 81C6 and its Fab fragment in human glioma xenografts in athymic mice.
Colapinto EV; Lee YS; Humphrey PA; Zalutsky MR; Friedman HS; Bullard DE; Bigner DD
Br J Neurosurg; 1988; 2(2):179-91. PubMed ID: 3267302
[TBL] [Abstract][Full Text] [Related]
19. Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report.
Bigner DD; Brown M; Coleman RE; Friedman AH; Friedman HS; McLendon RE; Bigner SH; Zhao XG; Wikstrand CJ; Pegram CN
J Neurooncol; 1995; 24(1):109-22. PubMed ID: 8523067
[TBL] [Abstract][Full Text] [Related]
20. A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen.
Sahagan BG; Dorai H; Saltzgaber-Muller J; Toneguzzo F; Guindon CA; Lilly SP; McDonald KW; Morrissey DV; Stone BA; Davis GL
J Immunol; 1986 Aug; 137(3):1066-74. PubMed ID: 3088107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
